Healthcare Equipment and Supplies
Company Overview of BrainScope Company, Inc.
BrainScope Company, Inc. operates as a medical neuro-technology company that focuses on the development of a hand-held medical device to aid medical professionals in the assessment of traumatic brain injuries and its milder forms (concussion). It serves military markets, emergency departments, pre-hospitals/urgent care units, and sports sectors worldwide. The company was incorporated in 2006 and is based in Bethesda, Maryland.
4350 East-West Highway
Bethesda, MD 20814
Founded in 2006
Key Executives for BrainScope Company, Inc.
Chief Executive Officer and Director
Vice President of Clinical Affairs
Compensation as of Fiscal Year 2016.
BrainScope Company, Inc. Key Developments
BrainScope Company, Inc. Announces FDA Clearance of the First Handheld Medical Device for Assessment of the Full Spectrum of Traumatic Brain Injury
Sep 26 16
BrainScope Company, Inc. announced that the United States Food and Drug administration has cleared the company to market the Ahead 300, its most advanced medical device for use in assessing traumatic brain injury (TBI). Developed in partnership with the U.S. Department of Defense, the Ahead 300 provides a multi-modal device of clinically relevant measures, offering clinicians a comprehensive panel of data to assist in their diagnosis of the full spectrum of TBI, including concussion. The Ahead 300 represents an evolution from the three BrainScope products that have previously received FDA clearance, and with its substantial additional capabilities, will be the first product the company will sell commercially. The Ahead 300 features BrainScope’s proprietary, patent-protected electroencephalography (EEG) capabilities utilizing sophisticated algorithms and machine learning to analyze head-injured patient data. Leveraging handheld smartphone technology and a proprietary disposable electrode headset, the Ahead 300 provides a rapid, objective assessment of the likelihood of the presence of TBI in patients who present with mild symptoms at the point of care. In addition to EEG capabilities, the Ahead 300 includes additional assessments providing clinicians with a digitized, streamlined report, delivering a comprehensive and objective panel of results to facilitate their differential diagnosis. BrainScope has focused on developing medical technology substantiated by clinical evidence emanating from over 20 clinical studies at 55 clinical sites over the past eight years. Stemming from this substantial clinical work, there is an extensive and growing bibliography of peer-reviewed publications underpinning the BrainScope technology. BrainScope has also developed a broad Intellectual Property portfolio now consisting of 100 issued and pending patents worldwide.
BrainScope Company, Inc. Appoints Andrew Holman as Chief Commercial Officer
Jul 21 16
BrainScope Company, Inc. announced the appointment of Andrew Holman as Chief Commercial Officer. With over 20 years experience in sales and marketing in top echelon medical device companies, Holman will lead the commercialization efforts for BrainScope as it approaches the anticipated launch of its first product. Holman most recently served as President of Corporate Development for Greatbatch, Inc., with prior roles as Chief Commercial Officer and Executive Vice President of Global Sales and Marketing.
BrainScope Company, Inc. Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-02-2015 08:50 AM
Nov 23 15
BrainScope Company, Inc. Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-02-2015 08:50 AM. Venue: Lotte New York Palace, New York, New York, United States. Speakers: Michael E. Singer, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|